GlassScriptPhysician profile
Charles J Odgers
NPI 1841201399
$10,507.83
in general payments reported to CMS, 2019-2025
28 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $784 · 2021: $2,950 · 2022: $184 · 2023: $4,449 · 2024: $232 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,323 · Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,322.52 |
| Food and Beverage | $2,424.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,525.85 | 2019-2025 | Blueprint Patient Specific Instrumentation, Aequalis Flex Revive, Pangea |
| Arthrex, INC. | $1,164.27 | 2019-2023 | |
| Eclipse Technology Solutions INC. | $1,140.77 | 2023-2025 | |
| Liberty Surgical INC. | $844.37 | 2019-2021 | |
| Encore Medical, LP | $763.74 | 2021 | |
| Depuy Synthes Sales INC. | $313.28 | 2019-2025 | Orthovisc, Monovisc |
| Heraeus Medical, LLC. | $236.42 | 2023-2025 | Palacos |
| Zimmer Biomet Holdings, INC. | $185.47 | 2023-2025 | Gel-One Cross-Linked Hyaluronate |
| Ferring Pharmaceuticals INC. | $177.20 | 2019-2025 | Euflexxa |
| Pacira Therapeutics, INC. | $169.29 | 2019-2021 | |
| Smith+Nephew, INC. | $137.27 | 2019-2022 | |
| Amgen INC. | $94.89 | 2020-2025 | Evenity |
| Vertex Pharmaceuticals Incorporated | $91.30 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $87.32 | 2019 | |
| Abbvie INC. | $85.47 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $82.18 | 2019-2021 | |
| Djo, LLC | $68.82 | 2019-2025 | Cmf |
| Abbott Laboratories | $59.76 | 2024-2025 | Octrode |
| Avanos Medical | $47.55 | 2022 | |
| Sebela Pharmaceuticals INC. | $36.00 | 2019 | |
| Hikma Pharmaceuticals USA | $36.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.94 | 2021-2023 | |
| Kyowa Kirin, INC. | $29.03 | 2023 | |
| Fidia Pharma USA INC. | $23.37 | 2019 | |
| Electronic Waveform Lab, INC. | $22.76 | 2023 | |
| Radius Health, INC. | $17.24 | 2021 | |
| Octapharma USA, INC. | $17.24 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $16.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Odgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.